HAS1 and ovarian cancer: We investigated the effect of this direct FXa inhibitor on proliferation, mortality, cell migration, production of MMPs and expression of oncogenes and HAS in OVCAR3 (ovarian cancer cells), MDA MB 231 (breast cancer cells), CaCO-2 (colon cancer), LNCaP (prostate cancer) and U937 (histiocytic lymphoma), as the procoagulant activity may differ in different cancer cell lines [35–36].